Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis

Tohru Ikuta, George Atweh, Vassiliki Boosalis, Gary L. White, Silvana D.A. Fonseca, Michael Boosalis, Douglas V. Faller, Susan P. Perrine

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Cooley's anemia is characterized by a deficiency of β-globin chains, a relative excess of α-globin chains, and consequent accelerated programmed death of developing erythroid cells in the bone marrow. Increasing expression of the γ-globin genes to adequately balance excess α-globin chains can ameliorate this disorder. Butyrates induce γ-globin experimentally, but can also cause cell growth arrest with prolonged exposure or high concentrations, which in turn can accelerate apoptosis. To determine if these potentially opposing effects can be balanced to enhance therapeutic efficacy, an intermittent 'pulsed' regimen of butyrate was evaluated. Following induction of γ-globin mRNA and protein synthesis, total hemoglobin increased in β-thalassemia patients by more than 2 g/dl above baseline, and Hb F increased above 20% in 5/8 sickle cell patients from baseline levels of 2% Hb F. Specific regulatory regions were identified in the γ- and β-globin gene promoters to which new binding of transcription factors, including αCP2 (an activator of γ globin) occur during therapy solely in the butyrate-responsive patients. Other compounds which induce γ globin, derivatives of acetic, phenoxyacetic, propionic, and cinnamic acids, and dimethylbutyrate, are under investigation. Some of these newer γ-globin inducers (designated hemokines) provide better potential as therapeutics by also acting to increase hematopoietic cell viability and proliferation. Pharmacologic induction of expression of the endogenous γ-globin genes is a realistic approach to therapy of the β-globin disorders for many patients, with some effective agents available now and new therapeutics, with enhanced activities, under development.

Original languageEnglish (US)
Pages (from-to)87-99
Number of pages13
JournalAnnals of the New York Academy of Sciences
Volume850
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Globins
Butyrates
Hematopoiesis
Gene expression
Gene Expression
Genes
Pulse
Cells
Therapeutics
Gene
Erythroid Cells
Thalassemia
Nucleic Acid Regulatory Sequences
beta-Thalassemia
Propionates
Cell growth
Acetic Acid
Excess
Therapy
Induction

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis. / Ikuta, Tohru; Atweh, George; Boosalis, Vassiliki; White, Gary L.; Fonseca, Silvana D.A.; Boosalis, Michael; Faller, Douglas V.; Perrine, Susan P.

In: Annals of the New York Academy of Sciences, Vol. 850, 01.01.1998, p. 87-99.

Research output: Contribution to journalArticle

Ikuta, Tohru ; Atweh, George ; Boosalis, Vassiliki ; White, Gary L. ; Fonseca, Silvana D.A. ; Boosalis, Michael ; Faller, Douglas V. ; Perrine, Susan P. / Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis. In: Annals of the New York Academy of Sciences. 1998 ; Vol. 850. pp. 87-99.
@article{c8529690214e4faeb0e03a2ee350f1a5,
title = "Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis",
abstract = "Cooley's anemia is characterized by a deficiency of β-globin chains, a relative excess of α-globin chains, and consequent accelerated programmed death of developing erythroid cells in the bone marrow. Increasing expression of the γ-globin genes to adequately balance excess α-globin chains can ameliorate this disorder. Butyrates induce γ-globin experimentally, but can also cause cell growth arrest with prolonged exposure or high concentrations, which in turn can accelerate apoptosis. To determine if these potentially opposing effects can be balanced to enhance therapeutic efficacy, an intermittent 'pulsed' regimen of butyrate was evaluated. Following induction of γ-globin mRNA and protein synthesis, total hemoglobin increased in β-thalassemia patients by more than 2 g/dl above baseline, and Hb F increased above 20{\%} in 5/8 sickle cell patients from baseline levels of 2{\%} Hb F. Specific regulatory regions were identified in the γ- and β-globin gene promoters to which new binding of transcription factors, including αCP2 (an activator of γ globin) occur during therapy solely in the butyrate-responsive patients. Other compounds which induce γ globin, derivatives of acetic, phenoxyacetic, propionic, and cinnamic acids, and dimethylbutyrate, are under investigation. Some of these newer γ-globin inducers (designated hemokines) provide better potential as therapeutics by also acting to increase hematopoietic cell viability and proliferation. Pharmacologic induction of expression of the endogenous γ-globin genes is a realistic approach to therapy of the β-globin disorders for many patients, with some effective agents available now and new therapeutics, with enhanced activities, under development.",
author = "Tohru Ikuta and George Atweh and Vassiliki Boosalis and White, {Gary L.} and Fonseca, {Silvana D.A.} and Michael Boosalis and Faller, {Douglas V.} and Perrine, {Susan P.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1111/j.1749-6632.1998.tb10466.x",
language = "English (US)",
volume = "850",
pages = "87--99",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis

AU - Ikuta, Tohru

AU - Atweh, George

AU - Boosalis, Vassiliki

AU - White, Gary L.

AU - Fonseca, Silvana D.A.

AU - Boosalis, Michael

AU - Faller, Douglas V.

AU - Perrine, Susan P.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Cooley's anemia is characterized by a deficiency of β-globin chains, a relative excess of α-globin chains, and consequent accelerated programmed death of developing erythroid cells in the bone marrow. Increasing expression of the γ-globin genes to adequately balance excess α-globin chains can ameliorate this disorder. Butyrates induce γ-globin experimentally, but can also cause cell growth arrest with prolonged exposure or high concentrations, which in turn can accelerate apoptosis. To determine if these potentially opposing effects can be balanced to enhance therapeutic efficacy, an intermittent 'pulsed' regimen of butyrate was evaluated. Following induction of γ-globin mRNA and protein synthesis, total hemoglobin increased in β-thalassemia patients by more than 2 g/dl above baseline, and Hb F increased above 20% in 5/8 sickle cell patients from baseline levels of 2% Hb F. Specific regulatory regions were identified in the γ- and β-globin gene promoters to which new binding of transcription factors, including αCP2 (an activator of γ globin) occur during therapy solely in the butyrate-responsive patients. Other compounds which induce γ globin, derivatives of acetic, phenoxyacetic, propionic, and cinnamic acids, and dimethylbutyrate, are under investigation. Some of these newer γ-globin inducers (designated hemokines) provide better potential as therapeutics by also acting to increase hematopoietic cell viability and proliferation. Pharmacologic induction of expression of the endogenous γ-globin genes is a realistic approach to therapy of the β-globin disorders for many patients, with some effective agents available now and new therapeutics, with enhanced activities, under development.

AB - Cooley's anemia is characterized by a deficiency of β-globin chains, a relative excess of α-globin chains, and consequent accelerated programmed death of developing erythroid cells in the bone marrow. Increasing expression of the γ-globin genes to adequately balance excess α-globin chains can ameliorate this disorder. Butyrates induce γ-globin experimentally, but can also cause cell growth arrest with prolonged exposure or high concentrations, which in turn can accelerate apoptosis. To determine if these potentially opposing effects can be balanced to enhance therapeutic efficacy, an intermittent 'pulsed' regimen of butyrate was evaluated. Following induction of γ-globin mRNA and protein synthesis, total hemoglobin increased in β-thalassemia patients by more than 2 g/dl above baseline, and Hb F increased above 20% in 5/8 sickle cell patients from baseline levels of 2% Hb F. Specific regulatory regions were identified in the γ- and β-globin gene promoters to which new binding of transcription factors, including αCP2 (an activator of γ globin) occur during therapy solely in the butyrate-responsive patients. Other compounds which induce γ globin, derivatives of acetic, phenoxyacetic, propionic, and cinnamic acids, and dimethylbutyrate, are under investigation. Some of these newer γ-globin inducers (designated hemokines) provide better potential as therapeutics by also acting to increase hematopoietic cell viability and proliferation. Pharmacologic induction of expression of the endogenous γ-globin genes is a realistic approach to therapy of the β-globin disorders for many patients, with some effective agents available now and new therapeutics, with enhanced activities, under development.

UR - http://www.scopus.com/inward/record.url?scp=0031822681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031822681&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.1998.tb10466.x

DO - 10.1111/j.1749-6632.1998.tb10466.x

M3 - Article

C2 - 9668531

AN - SCOPUS:0031822681

VL - 850

SP - 87

EP - 99

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -